Hypera Valuation

Is HYPE3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HYPE3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HYPE3 (R$30.08) is trading below our estimate of fair value (R$41.05)

Significantly Below Fair Value: HYPE3 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HYPE3?

Other financial metrics that can be useful for relative valuation.

HYPE3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.2x
Enterprise Value/EBITDA9.4x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does HYPE3's PE Ratio compare to its peers?

The above table shows the PE ratio for HYPE3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.5x
DESN Dottikon ES Holding
38.3xn/aCHF3.3b
506943 J. B. Chemicals & Pharmaceuticals
57.5x20.2%₹295.8b
002262 Jiangsu Nhwa Pharmaceutical
23.4x19.5%CN¥25.3b
600521 Zhejiang Huahai Pharmaceutical
26.6x23.6%CN¥23.7b
HYPE3 Hypera
11.2x13.7%R$18.1b

Price-To-Earnings vs Peers: HYPE3 is good value based on its Price-To-Earnings Ratio (11.2x) compared to the peer average (37x).


Price to Earnings Ratio vs Industry

How does HYPE3's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.5%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: HYPE3 is good value based on its Price-To-Earnings Ratio (11.2x) compared to the Global Pharmaceuticals industry average (24.5x).


Price to Earnings Ratio vs Fair Ratio

What is HYPE3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HYPE3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.2x
Fair PE Ratio12.2x

Price-To-Earnings vs Fair Ratio: HYPE3 is good value based on its Price-To-Earnings Ratio (11.2x) compared to the estimated Fair Price-To-Earnings Ratio (12.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HYPE3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentR$30.08
R$41.12
+36.7%
14.9%R$56.00R$31.00n/a12
Apr ’25R$32.31
R$42.62
+31.9%
11.6%R$56.00R$36.00n/a12
Mar ’25R$34.20
R$43.08
+26.0%
10.9%R$56.00R$36.00n/a12
Feb ’25R$31.97
R$43.53
+36.2%
11.6%R$58.00R$36.00n/a12
Jan ’25R$35.75
R$45.13
+26.2%
11.3%R$58.00R$36.00n/a12
Dec ’24R$34.20
R$45.13
+32.0%
11.3%R$58.00R$36.00n/a12
Nov ’24R$30.73
R$46.30
+50.7%
11.5%R$58.00R$36.00n/a12
Oct ’24R$37.14
R$51.63
+39.0%
6.2%R$58.00R$47.20n/a12
Sep ’24R$39.80
R$52.28
+31.3%
7.1%R$60.00R$47.20n/a13
Aug ’24R$43.43
R$51.97
+19.7%
7.0%R$60.00R$47.20n/a13
Jul ’24R$46.01
R$50.51
+9.8%
5.6%R$58.00R$47.00n/a13
Jun ’24R$41.59
R$50.51
+21.4%
5.6%R$58.00R$47.00n/a13
May ’24R$37.25
R$51.10
+37.2%
6.3%R$58.00R$47.00n/a14
Apr ’24R$37.70
R$52.96
+40.5%
6.9%R$61.00R$47.20R$32.3114
Mar ’24R$41.27
R$52.23
+26.5%
8.6%R$61.00R$42.00R$34.2015
Feb ’24R$45.96
R$51.49
+12.0%
10.5%R$61.00R$41.00R$31.9715
Jan ’24R$45.20
R$51.89
+14.8%
10.6%R$61.00R$41.00R$35.7515
Dec ’23R$44.38
R$51.89
+16.9%
10.6%R$61.00R$41.00R$34.2015
Nov ’23R$48.91
R$51.23
+4.7%
9.6%R$58.00R$41.00R$30.7315
Oct ’23R$44.25
R$49.96
+12.9%
7.6%R$56.80R$42.00R$37.1414
Sep ’23R$43.72
R$49.03
+12.1%
9.1%R$56.80R$42.00R$39.8014
Aug ’23R$42.25
R$46.54
+10.2%
10.3%R$55.00R$36.30R$43.4312
Jul ’23R$37.57
R$45.63
+21.4%
10.4%R$55.00R$36.30R$46.0112
Jun ’23R$41.76
R$44.38
+6.3%
11.4%R$55.00R$36.30R$41.5912
May ’23R$37.42
R$43.65
+16.6%
12.1%R$55.00R$36.30R$37.2512
Apr ’23R$39.22
R$42.98
+9.6%
13.1%R$55.00R$36.30R$37.7012

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.